HBOT Conversations:

Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy

Subscribe. Join the discussion. Share the hope.

 

 

 

Listen to or Watch the HBOT Conversations Podcast

Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:

Watch the HBOT Conversations Podcast

Laurie Anderson – Healing COVID with HBOT (Part 3)

Laurie Anderson – Healing COVID with HBOT (Part 3)

Laurie Anderson – Healing COVID with HBOT (Part 2)

Laurie Anderson – Healing COVID with HBOT (Part 2)

Laurie Anderson – Healing COVID with HBOT (Part 1)

Laurie Anderson – Healing COVID with HBOT (Part 1)

Tom Fox (Part 2)

Tom Fox (Part 2)

Tom Fox (Part 1)

Tom Fox (Part 1)

Elena Schertz & Tom Fox (Part 5)

Elena Schertz & Tom Fox (Part 5)

Elena Schertz & Tom Fox (Part 4)

Elena Schertz & Tom Fox (Part 4)

Elena Schertz & Tom Fox (Part 3)

Elena Schertz & Tom Fox (Part 3)

Elena Schertz & Tom Fox (Part 2)

Elena Schertz & Tom Fox (Part 2)

Elena Schertz & Tom Fox (Part 1)

Elena Schertz & Tom Fox (Part 1)

Dr. Jay Stevens  – Optimizing Health & Longevity

Dr. Jay Stevens – Optimizing Health & Longevity

Evan Fernandez – Warriors on the Water

Evan Fernandez – Warriors on the Water

Dr. Jay Stevens  – Head Injuries

Dr. Jay Stevens – Head Injuries

Jim Hooker – HBOT for Vets (Part 2)

Jim Hooker – HBOT for Vets (Part 2)

Jim Hooker – HBOT for Vets (Part 1)

Jim Hooker – HBOT for Vets (Part 1)

Dr. Hemal Mehta & Vibrant Health University

Dr. Hemal Mehta & Vibrant Health University

Dr. Jay Stevens  – Sports-Related Injuries & Performance Enhancement

Dr. Jay Stevens – Sports-Related Injuries & Performance Enhancement

Ernie Harrison: Veteran with PTSD & TBI

Ernie Harrison: Veteran with PTSD & TBI

Dr. Hemal Mehta & Regenerative Medicine

Dr. Hemal Mehta & Regenerative Medicine

Dr. Hemal Mehta & Fasting (Part 2)

Dr. Hemal Mehta & Fasting (Part 2)

Dr. Hemal Mehta & Fasting (Part 1)

Dr. Hemal Mehta & Fasting (Part 1)

Dr. Jay Stevens – “Learn The Right Fast”

Dr. Jay Stevens – “Learn The Right Fast”

Dr. Peter Canaday (Part 2)

Dr. Peter Canaday (Part 2)

Dr. Peter Canaday (Part 1)

Dr. Peter Canaday (Part 1)

Dr. Paul Harch & Viral / Bacterial Infections

Dr. Paul Harch & Viral / Bacterial Infections

Dr. Paul Harch & 8,101 Genes

Dr. Paul Harch & 8,101 Genes

Dr. Paul Harch & Autism

Dr. Paul Harch & Autism

Dr. Paul Harch & Strokes

Dr. Paul Harch & Strokes

Dr. Paul Harch & Birth Injuries/ Cerebral Palsy

Dr. Paul Harch & Birth Injuries/ Cerebral Palsy

Dr. Paul Harch & The Science Behind the Practice

Dr. Paul Harch & The Science Behind the Practice

Dr. Paul Harch & TBI

Dr. Paul Harch & TBI

Dr. Paul Harch & Thermal Burns

Dr. Paul Harch & Thermal Burns

Dr. Paul Harch & Inflammation

Dr. Paul Harch & Inflammation

Robert Beckman & TreatNow.org

Robert Beckman & TreatNow.org

Elena Schertz & Extivita RTP

Elena Schertz & Extivita RTP

Subscribe Now, It’s Free !

Name(Required)

Recent HBOT News

A Pilot Study of Short-Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine in Patients with Diabetic Foot Ulcer Wagner 3-4.

To evaluate the short-duration hyperbaric oxygen therapy (HBOT) can improve HbA1c levels, leukocyte count, and serum creatinine levels in patients with diabetic foot ulcer (DFU) Wagner 3-4. Blood samples from all DFU patients at Sanglah General Hospital, Denpasar, were taken for HbA1c, leukocyte, and serum creatinine test before debridement procedure, and the patients were then grouped into either standard therapy or standard therapy with HBOT for 10 sessions (combination therapy). At the end of therapy, all blood tests were resumed. Each group consisted of 15 patients. Results of laboratory analysis before and after treatment were significant regarding decrease of HbA1c levels in standard therapy (10.98 ± 2.37 % to 9.70 ± 2.46 %; p = 0.006), HbA1c levels in combination therapy (9.42 ± 1.96 % to 7.07 ± 1.16 %; p < 0.001), and leukocyte count in combination therapy (13.97 ± 6.24 x 10 cells/L to 8.84 ± 2.88 x 10 cells/L; p = 0.009).